Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Imai

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Translational Andrology and Urology|December 10, 2025
Apalutamide-induced rash and relative dose intensity in metastatic castration-sensitive prostate cancer: a multicenter Japanese cohort studyFumihiko Urabe, Hajime Onuma, Kojiro Tashiro, et al.
The Prostate|April 17, 2026
Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine FeaturesTatsuya Shimomura, Masaya Murakami, Kanako Kasai, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Urologic Oncology|May 10, 2024
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective studyKatsuki Muramoto, Fumihiko Urabe, Yuhei Koike, et al.
International Journal of Clinical Oncology|December 9, 2025
Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumabMana Nakata, Fumihiko Urabe, Yu Imai, et al.
Japanese Journal of Clinical Oncology|June 26, 2024
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomesShun Saito, Hidetsugu Takahashi, Yuji Yata, et al.
Japanese Journal of Clinical Oncology|August 30, 2023
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective studyKazuhiro Takahashi, Fumihiko Urabe, Yushi Suhara, et al.
Translational Andrology and Urology|December 19, 2024
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort studyRyotaro Yamaguchi, Hirokazu Kagawa, Kentaro Yoshihara, et al.
International Journal of Clinical Oncology|October 20, 2023
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort studyHirokazu Kagawa, Fumihiko Urabe, Yuria Kiuchi, et al.
Translational Andrology and Urology|April 9, 2024
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective studyNaoki Uchida, Fumihiko Urabe, Yushi Suhara, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Translational Andrology and Urology|December 10, 2025
Apalutamide-induced rash and relative dose intensity in metastatic castration-sensitive prostate cancer: a multicenter Japanese cohort studyFumihiko Urabe, Hajime Onuma, Kojiro Tashiro, et al.
The Prostate|April 17, 2026
Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine FeaturesTatsuya Shimomura, Masaya Murakami, Kanako Kasai, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Urologic Oncology|May 10, 2024
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective studyKatsuki Muramoto, Fumihiko Urabe, Yuhei Koike, et al.
International Journal of Clinical Oncology|December 9, 2025
Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumabMana Nakata, Fumihiko Urabe, Yu Imai, et al.
Japanese Journal of Clinical Oncology|June 26, 2024
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomesShun Saito, Hidetsugu Takahashi, Yuji Yata, et al.
Japanese Journal of Clinical Oncology|August 30, 2023
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective studyKazuhiro Takahashi, Fumihiko Urabe, Yushi Suhara, et al.
Translational Andrology and Urology|December 19, 2024
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort studyRyotaro Yamaguchi, Hirokazu Kagawa, Kentaro Yoshihara, et al.
International Journal of Clinical Oncology|October 20, 2023
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort studyHirokazu Kagawa, Fumihiko Urabe, Yuria Kiuchi, et al.
Translational Andrology and Urology|April 9, 2024
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective studyNaoki Uchida, Fumihiko Urabe, Yushi Suhara, et al.
Pageof 8